Condition

mCRPC (Metastatic Castration-resistant Prostate Cancer)

ClinicalTrials.gov condition label

Clinical trials13
Recruiting12
Common interventions20
Lead sponsors shown13

Clinical trials

13 shown
A Study in Patients With Metastatic Castration-Resistant Prostate CancerNCT07719361 · 2026-07-01
RECRUITING
A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate CancerNCT07581184 · 2026-06-17
RECRUITING
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or DarolutamideNCT06844383 · 2026-05-04
RECRUITING
SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPCNCT07451795 · 2026-03-02
RECRUITING
A Study of MHB048C in Patients With Advanced Solid TumorsNCT07192120 · 2026-01-16
RECRUITING
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)NCT07103018 · 2025-11-21
RECRUITING
Four-Timepoint Multi-tracer PET Imaging to Characterize Metastatic prOstate Cancer HeterogeneityNCT07302763 · 2025-11-04
RECRUITING
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate CancerNCT06801236 · 2025-05-12
RECRUITING
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPCNCT06785636 · 2025-02-07
RECRUITING
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate CancerNCT06190899 · 2024-01-01
RECRUITING
Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate CancerNCT06702995 · 2023-04-19
RECRUITING
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing TumorsNCT05283330 · 2022-12-22
RECRUITING
Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate CancerNCT07623460 · 2026-09-01
NOT_YET_RECRUITING

Trial status mix

RECRUITING12
NOT_YET_RECRUITING1

Phase mix

PHASE19
PHASE27
NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.